Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Etanercept inhibits pro-inflammatory cytokines expression in titanium particle-stimulated peritoneal macrophages

Zhirong Chen¹, Liang Zhan¹, Zhidong Lu¹, Yi Ma², Zhihui Gao¹, Haohui Guo¹, Long Pang¹, Qunhua Jin¹

For correspondence:- Qunhua Jin Email: jinqunhua@sina.com Tel:+9516743581

Received: 29 October 2014 Accepted: 9 April 2015 Published: 29 June 2015

Citation: Chen Z, Zhan L, Lu Z, Ma Y, Gao Z, Guo H, et al. Etanercept inhibits pro-inflammatory cytokines expression in titanium particle-stimulated peritoneal macrophages. Trop J Pharm Res 2015; 14(6):983-987 doi: 10.4314/tjpr.v14i6.7

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the inhibitory role of Etanercept in pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 production in titanium (Ti) particle stimulated macrophages.

Methods: Peritoneal macrophages were stimulated with 1 × 10⁹ Ti particles and treated simultaneously with or without 10, 100, or 1000 ng/mL Etanercept. The levels of TNF-α, IL-1β and IL-6 in the culture supernatants were measured using ELISA.

Results: Titanium particles could stimulate TNF-α, IL-1β and IL-6 secretion in peritoneal macrophages. Etanercept inhibited Ti particle-induced TNF-α release by 29.7 % at 10 ng/ml (19.19 ± 4.72 pg/mL, p < 0.01), 49.3 % at 100 ng/mL (13.83 ± 3.72 pg/ml, p < 0.01) and 60.4 % at 1000 ng/mL (10.82 ± 3.87 pg/mL, p < 0.001), IL-1β release by 5.23 % at 10 ng/mL (34.79 ± 7.83 pg/mL, p > 0.05), 21.06 % at 100 ng/mL (28.98 ± 4.81 pg/mL, p < 0.01) and 29.83 % at 1000 ng/mL (25.76 ± 5.23 pg/ml, p < 0.001), and IL-6 release by 38.69 % at 10 ng/mL (256.8 ± 99.56 pg/mL, p < 0.01), by 42.13 % at 100 ng/mL (242.4 ± 33.26 pg/mL, p < 0.01) and 53.4 % at 1000 ng/ml (195.2 ± 48.82 pg/mL, p < 0.001).

Conclusion: Etanercept has potent ability to prevent wear debris–induced osteolysis and may be valuable as a therapeutic agent for the treatment of prosthetic loosening in humans.

Keywords: Etanercept; titanium particle; proinflammatory cytokines; peritoneal macrophages